title: Experiences with the rectal use of trimethoprim.
abstract: The possibility of rectal use of trimethoprim was studied. The in-vitro liberation of the drug from 24 different suppository bases was examined and the results used to select bases for in-vivo examination. The in-vitro liberation from the suppositories containing 50-200 mg trimethoprim was studied by the method of dynamic diffusion, and the released drug content was measured spectrophotometrically. The in-vivo examinations were performed in anaesthetized rats. The concentration of trimethoprim in blood was determined by bioassay. The absorption of the drug in the form of oral suspension, rectal solution and suppository was also studied. The pharmacokinetic parameters obtained after blood-level curve fitting were compared by use of the MedUSA 1.6 program. The best in-vivo results were achieved with the lipohydrophilic Witepsol W 35 vehicle containing 10% polysorbate 20 and 10% polysorbate 61 (bioavailability = 63.8%) and with Witepsol W 35 containing 10% polysorbate 60 (bioavailability = 63.8%). The results for hydrophilic Macrogol 1540 vehicle containing 5% of Macrogol 400 were only slightly worse (bioavailability = 52.9%). In the case of the lipohydrophilic Witepsol W 35 vehicle with 10% polysorbate 20 and 10% polysorbate 61 content a significant negative exponential relationship was found between the administered doses and their respective bioavailability values; this tendency was also observed during in-vitro examinations. When incorporated in the appropriate vehicle trimethoprim was absorbed well. With three vehicles the extent of absorption exceeded that for oral administration on the same model (bioavailability = 38.8%). Trimethoprim rectal suppositories, which are formulated with the vehicles having the best in-vitro and in-vivo results, are suitable for clinical pharmacological investigation.
authors.affiliation: Department of Pharmacodynamics, Albert Szent-Györgyi Medical University, Hungary.
authors.forename: J
authors.initials: J
authors.lastname: Sallai
authors.forename: A
authors.initials: A
authors.lastname: Vernyik
authors.forename: G
authors.initials: G
authors.lastname: Regdon
authors.forename: S
authors.initials: S
authors.lastname: Gombkŏtŏ
authors.forename: J
authors.initials: J
authors.lastname: Németh
authors.forename: G
authors.initials: G
authors.lastname: Regdon
mesh_terms: D000284:Administration, Oral; D000285:Administration, Rectal; D000818:Animals; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D004058:Diffusion; D005260:Female; D007275:Injections, Intravenous; D014677:Pharmaceutical Vehicles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D012996:Solutions; D013488:Suppositories; D014295:Trimethoprim / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000892:Anti-Infective Agents, Urinary; D014677:Pharmaceutical Vehicles; D012996:Solutions; D013488:Suppositories; D014295:Trimethoprim